


Effect of add-on transcranial alternating current stimulation in
major depressive disorder: a randomized controlled trial

Journal of Clinical Psychiatry

Volume 75, Number 10, October 2014

Copyright © 2014 by Lippincott Williams & Wilkins
DOI: 10.1097/JCP.0000000000000000



Major depressive disorder is a common disease affecting more than 100 million people worldwide and a major contributor to the overall global burden of disease. World Health Organization therefore the development of effective accessible interventions for it is a high priority for the improvement of public health. First-line evidence-based treatments include selective serotonin reuptake inhibitors and cognitive behavioral therapy. However, not all patients do not adequately respond to first-line treatments. It is generally in the form of a combination of antidepressants and cognitive behavioral therapy. Therefore, there is an urgent need for new treatment options.

Transcranial alternating current stimulation (tACS) is a neuromodulation technique that applies electrical currents with increasing intensity to the scalp to regulate cortical excitability and spontaneous neuronal activity. It has been used for over a decade in different fields (for instance cognitive neuroscience) and it has only been applied in psychiatric clinical research in recent years. It represents most clinical studies on depression used the frequencies of 10 Hz or 20 Hz and stimulation sites selected in the frontal lobe. The studies also reported that a current of 2 mA and a frequency of 10 Hz can deliver electrical currents to deep brain tissues. It has also found that a frequency of 10 Hz can increase the levels of endorphins and neurotransmitters (including serotonin in the brainstem, norepinephrine and dopamine) and endorphins and neurotransmitters changes are related to the neurobiological mechanisms for improving depression symptoms.

The study examining tACS's role in treating depression revealed that it is effective in alleviating depressive symptoms in over 60% of first-episode drug-naïve patients. It was included in the study to generalize a list of its findings as limited. Not every study examined the effectiveness of combined tACS but it did not limit the type and dose of the antidepressants used in the study. The antidepressant effectiveness of different studies varied. It is still in the form of a combination of antidepressants and tACS could enhance the effectiveness of antidepressants and might be a good alternative for antidepressants. A meta-analysis in addition to the antidepressant mechanism of tACS is common and currently unclear.

Depression is related to a complex picture of altered brain oscillations. The resting-state low-frequency bands (delta, theta and alpha) in electroencephalogram (EEG) especially the alpha band were enhanced in patients with depression in terms of either power or coherence. Moreover, the enhancement persisted even after an individual changed from an eye-closed to an eye-open state. In patients with a high-amplitude oscillatory activity (HAA) call in the alpha frequency band. It could be a sign of oscillations serving important functions in the healthy brain. The increased alpha oscillation in patients with depression represents a state of neuronal inactivity leading to disrupted affective processing. Researchers found that the left prefrontal cortex is inhibited and increased alpha frequency power during the processing of positive emotions in individuals with depression. Hence, the elevated amplitude of left frontal alpha oscillations is theorized to correspond to a reduction in alpha frequency power. The experience of emotion is related to alpha stimulation may produce a selective decrease in left frontal alpha oscillations towards images rated as positive.

Therefore, we conducted a double-blind study to evaluate the feasibility, safety and effectiveness of tACS as a treatment for depression. We aim to understand how tACS affects neuronal activity. We measured alpha power changes as our secondary outcome using high-resolution EEG.

2.1. Study Design and participants

The double-blind randomized sham-controlled trial was performed at Beijing Normal University Medical Center from January to December. The trial received institutional review board approval and was performed in accordance with ethical principles originating in the Declaration of Helsinki and as reported in accordance with the reporting guidelines. The study was registered on the ClinicalTrials.gov website before enrollment. The investigators (JTS, YC) registered on the ClinicalTrials.gov website before enrollment. All patients provided written informed consent prior to enrollment. The trial was completed on reaching the predetermined target enrollment numbers. After the trial all patients entered the depression cohort and were followed up for 6 weeks.

2.2. Sample size calculation

The present trial is only one randomized controlled trial in estimating the effectiveness of tACS as an add-on to antidepressants in treating depression. However, we found that the effect size derived from this study is extremely large. The sample size calculated based on this effect size as a pilot study would be too small to verify the effect statistically. Therefore, we used a conservative estimate of effect size as considered the criteria for large effects to calculate our sample size. Instead, we applied to calculate the sample size based on effect size = 0.2 (two-sided) = 0.05 = 0.05 and = 0.05 and found after calculation that each group would require approximately 100 participants. It is a drop-out rate. Therefore, the experimental and control groups would need approximately 120 participants each, making a total sample size of 240.

2.3. Inclusion/exclusion criteria

Participants were recruited through physician referrals and posters. The inclusion criteria were being 18–65 years old, being diagnosed with a psychiatrist using the structured clinical interview for diagnostic and statistical manual of mental disorders (5th Edition) - giving a total score of 10 or more on the Hamilton Rating Scale for Depression - and a Hamilton Depression score of 10 or more. They had not received antidepressant medications for the current depressive episode. Being able to understand and sign the informed consent form of the inclusion criteria were giving a current or history of seizures, epilepsy, drooping of the central nervous system tumors or acute brain injury and infection. They had a significant risk of suicide indicated a score of 10 or more on the Hamilton Depression Rating Scale or a history of suicidal behavior. They had been exposed to electroconvulsive therapy. Excluded were electroconvulsive therapy, Electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, or other neurostimulation treatments in one month before enrollment. Being pregnant or breastfeeding. Patients with any severe organic diseases or were in an unstable condition because of an organic disease. The trial protocol also contains additional inclusion and all exclusion criteria is available in Supplement.

2.4. Randomization, concealment, and blinding

Computer-generated randomization schedule using randomized location random assigned eligible patients to the active and sham treatment groups in a 1:1 ratio. A random number table containing randomization sequences as generated by the software. A statistician not involved in conducting the trial (second nurse) also not involved in conducting this trial. The

group assignment results generated from the random number table in identical sequential numbered opaque sealed envelopes. Each patient received a sealed envelope at enrollment. In all, on the patient's first day of enrollment or the day that the patient received the first stimulation session, the envelope containing group assignment information would be opened by a researcher.

In the double-blind randomization process and throughout the trial, the active or sham groups as well as the active or sham stimulation devices were represented by the letters 'A' and 'B' to avoid errors. The information on the letter assigned to a patient so that all individuals involved in the trial were blinded to the type of stimulation (active or sham) they were receiving. Also, there was no difference between active and sham stimulation devices in terms of appearance and the appearance of the patient's senses so that the patient and the operator could not distinguish the instrument as the active stimulation device based on the appearance of the device or the subjective feelings of the patients. After statistical analyses in this study were completed, unblinding was performed.

2.5. Procedures

Participants were asked to sit comfortably in reclining chairs while receiving international medical products administration. The electrode was placed on the forehead at the international placement system 10 × 10 cm electrodes were placed on each side of the mastoid. The stimulation waveform includes ramp-up and ramp-down periods of 10 s and a 10 s rest interval. The waveform resembles a sine wave with an amplitude of 1 mA and is distributed equally from the frontal region to the mastoid areas. Amplitudes were ordered as 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256, and 512 μ A.

All participants received sessions of stimulation at 10 Hz and 10 min. The sham condition had no active stimulation from onset to offset. One 10-min session was administered at a fixed time each day during the 10-day trial. All participants were also asked to take 100 mg of escitalopram each day.

This study included the combined use of escitalopram throughout the 10-day period. All medications were taken orally after breakfast. Once daily medication was used in this study as 100 mg escitalopram tablets. Dose titration was performed. The researchers based on side effects and/or clinical course. The initial dose of escitalopram was 10 mg daily. It could be increased to 20 mg daily after 1 week based on the patient's condition. The dose could be further increased to 30 mg daily if necessary. Each increase in dose should be spaced a week apart and not less than 1 week apart.

2.6. EEG

Resting-state EEG data were collected at baseline and 10 days post-treatment using a 19-channel EEG system. The electrodes were positioned according to the standard international system. The sampling frequency was 250 Hz, and electrode impedance was $< 50 \Omega$. Participants were instructed to remain in a supine position with their eyes closed for 10 min during the EEG. In a cross-air condition, participants were instructed to breathe normally. Participants also completed a face-forward Stroop task. The results of the task are not presented here. The EEG data were processed using the EEGLAB toolbox. The data were segmented into 1-s segments. The channels were re-referenced to the bilateral mastoid independent component analysis and independent component analysis. Manual artifact removal after reprocessing the power spectral density of EEG data was estimated using the fast Fourier transform method and the power spectrum of

the alpha frequency band. The power spectrum was calculated to compare the changes in EEG power in the left frontal lobe. The electrodes were selected and averaged to represent the alpha power in the left frontal lobe.

2.7. Outcome measures

The primary efficacy endpoint was the change in the total score from baseline to the end of the treatment sessions. The secondary efficacy endpoints included clinical global impression of improvement, adverse effects, and the changes from baseline to the end of the treatment sessions. The scores on the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Insomnia Severity Index, and Somatic Symptom Scale were also assessed. The generalised anxiety disorder-7-item scale, the Patient Health Questionnaire-9, the Montgomery-Åsberg Depression Rating Scale, the Pittsburgh Sleep Quality Index, the Clinical Global Impressions-Severity of Illness scale, and the proportion of responders (defined as a reduction of 50% or more from baseline in the total score at each visit) and the efficacy were also assessed. EEG recordings were also collected. The adverse effects were evaluated. The adverse effects included vital signs, clinical laboratory evaluations, and electrocardiogram abnormalities. Serious adverse events were defined as untoward medical occurrences that resulted in death, life-threatening, permanent disability, or required hospitalization, resulting in persistent or significant disability.

2.8. Statistical analysis

The main analyses were completed on an intent-to-treat basis, meaning all randomized patients were included. Missing data for the primary outcome were imputed using the last observation carried forward method. The data at baseline were reported as mean (standard deviation) or median and interquartile range for continuous variables and count (percentage) for categorical variables. The primary endpoint was assessed using an independent-sample *t*-test based on data at the last observation carried forward. The imputation was performed to assess the sensitivity of the primary outcome to assess the robustness of the results. Sensitivity analyses included multiple imputation for monotone missing data. We fitted a regression model from observed data and potential predictors (i.e., age, sex, baseline score, etc.) to generate imputed values. We used multiple imputations to impute values for each missing observation and combined estimates using Rubin's EM algorithm. In the sensitivity analyses, a per-protocol analysis was also performed to examine whether the reductions in the scores on the primary and the response rates differed between the two groups. Sensitivity analyses evaluated the effect of the intervention on the primary scores using linear mixed modeling, based on all available data. It used imputation at the treatment group visit and the interaction group \times visit as fixed effects and the participant as a random effect. The secondary outcome (i.e., response rate) was assessed using the chi-square test. The reductions in the scores of each factor of the primary and the scores of the primary outcome were compared using the Wilcoxon rank-sum test. The independent-sample *t*-test was used to compare the differences between the reductions in the scores on the primary and the secondary outcomes in the active and sham groups. The correlation between the mean reduction in EEG and the mean reduction in the primary total score from baseline to the end of the study was evaluated using Pearson correlation analysis. The data were analyzed using R for Windows version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria). All values were two-sided and the differences were considered statistically significant when the *p* value was < 0.05 .

3.1. Participants

A total of 100 patients were assessed for eligibility and 66 patients met the inclusion criteria and were randomly allocated to the active treatment group (n = 33) or sham treatment group (n = 33). After randomization, seven patients in the sham treatment group were lost at follow-up and two patients in the active treatment group did not complete the study. The participants' demographic and clinical characteristics are summarized in Table 1. Overall, half of the participants were female. The mean values for other demographics included 45.2 ± 12.5 years for age, 165.3 ± 8.5 cm for height, and 70.5 ± 15.0 months for the duration of the recent episode. All participants were first episode and had a family history of mental disorders. Five patients started at a dose of 1 mg/day of escitalopram and increased to 2 mg/day after day 7. In total, 10 patients in each group increased to 2 mg/day after 7 days. In addition, one patient in the active treatment group did not take escitalopram and one patient in the sham treatment group maintained a dose of 1 mg/day.


3.2. Primary outcomes


No intention-to-treat analysis significant differences were found in the mean reduction of the HAM-D-21 scores at week 4 (t = 1.2, P = 0.23). There were also no statistically significant differences in the reduction of the HAM-D-21 scores at week 2 (t = 0.8, P = 0.42) and week 1 (t = 0.5, P = 0.61). Significant differences in the reduction of the HAM-D-21 scores of all outcomes at all time points are shown in Supplemental Materials Table 1.

3.3. Secondary outcomes

Significantly more patients in the active treatment group (n = 20) responded (defined as a reduction of 5 or more from

Basic information	Active treatment		Sham treatment	
	n	%	n	%
Gender				
Male	15	45.5	15	45.5
Female	18	54.5	18	54.5
Educational level				
Graduate	12	36.4	12	36.4
High school	15	45.5	15	45.5
Master doctor	6	18.2	6	18.2
Other	0	0	0	0
Country				
China	33	100	33	100
Marriage status				
Married	18	54.5	18	54.5
Unmarried	15	45.5	15	45.5
Monthly income (Chinese Yuan)				
< 1000	12	36.4	12	36.4
1000–2000	15	45.5	15	45.5
> 2000	6	18.2	6	18.2
Employment status				
Employed	18	54.5	18	54.5
Unemployed	15	45.5	15	45.5
Family history of mental disorder				
Yes	5	15.2	5	15.2
No	28	84.8	28	84.8
Duration of current episode (months)				
0–3	12	36.4	12	36.4
3–6	15	45.5	15	45.5
> 6	6	18.2	6	18.2
Duration of current episode (months)				
0–3	12	36.4	12	36.4
3–6	15	45.5	15	45.5
> 6	6	18.2	6	18.2
Baseline score of HAM-D-21				
17–20	12	36.4	12	36.4
21–24	15	45.5	15	45.5
> 24	6	18.2	6	18.2
Response rate of episode				
Yes	20	60.6	15	45.5
No	13	39.4	18	54.5





the early reductions of the 7-item Hamilton rating scale for depression – scores from baseline to weeks 2 and 4 in the active and sham groups. Note that the 7-item Hamilton rating scale for depression range – higher scores indicate more severe depressive symptoms. The error bars indicate the missing data of the 7-item Hamilton rating scale for depression scores for patients in the active and sham groups were imputed using the last observation carried forward (LOCF) method.

Baseline in the active group was significantly higher than in the sham group ($F(1, 15) = 10.1, P = 0.005$). The difference was also observed at week 2 ($F(1, 15) = 10.1, P = 0.005$), week 4 ($F(1, 15) = 10.1, P = 0.005$), and week 8 ($F(1, 15) = 10.1, P = 0.005$). Significant improvements in the active group were observed in the reductions in the scores on the depression and insomnia subscales of the HAM-D-7 and the actigraphy measures. The differences between the reductions in the depression and insomnia and somatic subscales of the HAM-D-7 in the active group were significantly larger than in the sham group ($F(1, 15) = 10.1, P = 0.005$). The score reduction in the active group was significantly larger than in the sham group ($F(1, 15) = 10.1, P = 0.005$). The differences between the reductions in the depression and insomnia scores in the active and sham groups were

not statistically significant ($P > 0.05$). The results are summarized in Table 1.

3.4. Sensitivity analysis

The results of the multiple imputation were consistent with those of the primary analysis. The results showed that the estimated mean depression reduction in the active group was larger than in the sham group ($F(1, 15) = 10.1, P = 0.005$). The per-protocol analysis also supported this result. The results are summarized in Table 1.


In addition, a mixed-effects model analysis of the treatment group, visit, and their interaction (group \times visit) as fixed effects and the participant as a random effect revealed a significant treatment group \times time interaction ($F(1, 15) = 10.1, P = 0.005$). The mean reduction in the depression score from baseline to week 8 was significantly greater in the active group than in the sham group. The least-squares mean reduction in the depression score from baseline to week 8 was significantly greater in the active group than in the sham group ($F(1, 15) = 10.1, P = 0.005$). The difference between the reductions in the depression score from baseline to week 8 in the active and sham groups was significantly larger than in the sham group ($F(1, 15) = 10.1, P = 0.005$). The results are summarized in Table 1.

3.5. Blinding integrity

To test the quality of the findings in our study, we asked participants to rate their confidence in the active and sham stimulation groups. The results showed that the majority of participants in the active group (66.67%) and the sham group (66.67%) were confident in the active and sham stimulation groups. The results are summarized in Table 1. The results showed that the majority of participants in the active group (66.67%) and the sham group (66.67%) were confident in the active and sham stimulation groups. The results are summarized in Table 1.

3.6. Mechanism exploration

To explore the mechanism of the effects of the active and sham stimulation groups, we assessed the changes in resting-state alpha power at the electrode sites. The results showed that the majority of participants in the active group (66.67%) and the sham group (66.67%) were confident in the active and sham stimulation groups. The results are summarized in Table 1.



The response rates at different visits in the active and sham groups. Note that the response was defined as a reduction in the 7-item Hamilton rating scale for depression – range – higher scores indicating more severe depressive symptoms. The missing data of the 7-item Hamilton rating scale for depression scores for patients in the active and sham groups were imputed using the last observation carried forward (LOCF) method.

et een t e treatment groups ut found no signi cant difference
 u lementar materials ig en e conduct d an in-de t
 e lorator anal sis n t e acti e t grou e found a correlation
 et een t e mean reduction of - in e e-closed state EE and De
 mean reduction in t e - total score from aseline to -ee e
 = P= lso in t e acti e t grou t e mean reduction of
 from aseline to ee in e e-closed state EE as signi cantl
 larger in t e res onders t an in t e non-res onders =
 n t e ot er and in t e s am t grou no consistent results
 ere found ig similar anal sis of t e e-o en state did not
 re eal an signi cant effects of t e stimulation on c anging al a o er
 a en t get er our results indicate t at β s effecti e in targeting
 al a oscillations in t e left frontal regions and t is c ange ad
 relations i it clinical Z mptoms tg

3.7. Safety

o serious adverse events ere o ser ed in t is trial e re ort ed
 general side effects in t e acti e t grou C com ared -it t e s am
 t grou K included eadac e com ared -it - \pm \pm

K

g

Kaf

n

iang

Ka

3

3

it antide ressants t e a erage reduction rate of t e scores reac ed le ander et al randomi ed atients it into t ree stud grou s of - t - t and s am stimulation and administered one -min inter ention session eac da for consecuti e da s along it antide ressants e res onse rate of t e - t grou at ee as signi cantl ig ert an e - and s am stimulation grou s suggesting t at - t ad a etter antide ressant ef cac e most relia le e idence in is for t it m n of t in drug-na e atients it s o ed a res onse rate of and a remission rate of after ee s of t treatment ic ere signi cantl ig ert an t e res onse and remission rates after s am stimulation and o e er t is stud onl included rst-e isode drug-na e atients and t e more signi cant treatment effect ma e e cause of t at not er studied t com ined it antide ressants in atients and found a romising clinical ef cac it a reduction of in t e scores in t e acti e grou and in t e s am grou at t e end of ee lt oug t is stud ad limitations and t e use of antide ressants as not limited t as an add-on to antide ressants ma e a good o tion for atients o need a fast effect long it ot er neuromodulations r also en ances t e clinical res onse to antide ressants and signi cantl accelerates t e alle iation of de ressi e s m toms in atients it stud of - ee r com ined it citalo ram found t at t e res onse rates in t e acti e grou ersus t e s am grou ere ersus at ee and ersus at ee stud of - ee r in com ination it aro etine found a res onse rate of and a remission rate of in t e acti e grou ic ere signi cantl ig ert an t ose in t e s am grou and at ee alt oug t ere as no signi cant difference at ee tudies of t as an add-on treatment to antide ressants also demonstrated t e snergistic effect of com ination t era ne stud found t at artici ants recei ing ee s of t com ined it sertraline ad a res onse rate of and a remission rate of signi cantl ig ert an t ose in t e sertraline-onl grou and n anot er stud atients it ere di ided into t ree grou s -min -min and s am t com ined it sertraline fter ten da s of t stimulation t e -min -min and s am grou s s o ed res onse rates of and and remission rates of and res ecti el e im ro ement in de ressi e s m toms as more su stantial in t e acti e stimulation grou s and t e im ro ement in t e -min grou as signi cantl larger t an in t e -min grou n summar t is e ected to e an effecti e add-on antide ressant treatment com ara le to r and t o - e er considering t at r and t a e een e aluated in large-scale multi-center trials ereas t as onl een studied in small-scale trials it s ould e noted t at t ere is a ris of false ositi e ndings and our ndings need to e con rmed larger trials in t e future e - scores did not re eal an signi cant treatment ad antage in t e acti e t stimulation grou o er t e s am stimulation grou ome studies a e found t at atients scored t emsel es ig ert on self-re ort measures t an t e clinicians rated t em E lanations for t is enomenon include t e differences in t e focus of t e clinician and atient o erestimation of s m tom se erit t e a-tients ig le els of an iet need for a ro al es eocial social desira ilit and ig le els of self-transcendence es eocial self-forgetfulness urt ermore after com aring eac factor in t e - e found t at t e factors de ressed mood insomnia and somati on s o ed more ronounced im ro ements ereas t ese s m toms ere lig ter eig ted in t e - t is difference ma e art of t e reasons t e c anges in t e total score ere not signi cant re ious studies e amining t e concordance et een self-re ort and clinician-rated measures ere inconsistent and t is is t e main reason most clinical trials ould use ot self-re ort and clinician-rated measures as outcome instruments it t e latter ser ing as t e measurement tool for t e rimar outcome

e as also used to assess t e se erit of t e atient's de ressi e s m toms and t e degree of im ro ement e - scores at ee suggested t at t e t grou ad more im ro ement t an e s am grou e results of t e - re ealed t e ositi e im act of on t e o erall clinical im ressi on of atients it lt oug t e is an instrument rel ing on t e su ecti e udgment of t e e aluators it ro ides im ortant information on t e effecti eness of treatment es eocial for t e e aluation of ractical clinical signi cance e safet of using ig currents is a concern n t is stud of t e artici ants com leted t e - ee stud e dro out rate as lo er t an t e estimation of suggesting t at t e t used in t is stud as safe and ell tolerated ll atients ere follo ed n for ad erse e ents and most side effects in t is stud ere mild some atients e erienced di iness eadac e and da time slee iness ore im ortantl t ere as a difference et een t e ad erse e ents in t e t o grou s re ious studies did not re ort side effects of da time slee iness o e er e o ser ed rolonged da time slee iness t at as clearl related to t e treatment it slee iness eing t e most ronounced at t e end of t alt oug it s ould e noted t at t is nding still needs to e alidated in future studies erefore it ma e necessar to notif atients o dri e e icles n addition no manic or o manic s m toms sei ures neurologic comlications o tical illusions deat s or ot er serious ad erse e ents ere o ser ed in our stud erall t e safet of t in com ination it antide ressants for t e treatment of as con rmed suggesting t at future clinical trials it t are feasi le e iological target of t e current stud as left frontal al a oscillations EE al a acti it is more ronounced it e es closed and al a o er as mmetr as een found to e more relia le it e es closed t an it e eso en e alteration of al a o er in our stud also occurred onl in t e e e-closed state is alteration ast oug t to re ect reduced neuronal acti it in t e left frontal lo e one of se eral e regions ere a normalities a e een found in rain imaging studies of de ressi on ne article as e amined EE c anges after recei ing t in atients it it found t at - t resulted in a signi cant reduction in al a oscillations in t e left frontal region it e es closed ereas no c anges ere found it - t n addition - t s o ed etter antide ressant effects not er stud found t at t indi iduali ed al a freuenc could reduce resting-state left frontal al a o er in atients it urt ermore t e reduction of left frontal al a oscillation t as s eci c for stimuli it ositi e alence ur stud also found a decrease in left frontal al a freuenc in a-tients ores onded to t e t treatment ut not in atients it no res onse e ot esi e t at t e antide ressant effect of t ma e related to t e decrease in left frontal al a o er e e act mec anism of t as not een determined studies a es o n t at t induces cortical oscillations entrainment and s i e-timing de endent lasticit tudies a e consistentl demonstrated t e locali ed o er en encement after t and a e found t at immediate t after-effects led to an increase in resting-state al a o er e transient al a o er en encement after a single t treatment ma e due to a stimulus dose t at is not suf cientl ersistent to induce long-term lasticit e increase in transient al a o er ma re ect neural induction of time-s nc roni ed cortical oscillations e ogenous stimuli ut e idence for long-term effects remains limited e found a decrease in al a o er after sessions of t ic is o osite to t e immediate effect suggesting t at re eated a lication of t ma lead to oscillator resetting ic in turn leads to a decrease in al a o er t roug a omeostatic mec anism roducing an antide ressant effect erefore t e results of t is stud once again suggested t at t e intrinsic regulation of al a oscillations ma e an im ortant mec anism for t e antide ressant effect of t is stud as some limitations irst e onl o ser ed t e ef cac in t e acute ase and e onl included a - ee follo -u ic is rat ers ort com ared to current est- ractice s in erefore

The maintenance effect still needs to be further investigated. Second, we used only the intermittent and a brief stimulation position. The antidepressant efficacy of different frequencies, currents, and electrode combinations is unknown. It is unclear whether the tEE at different locations and frequencies changed. Also, all patients used antidepressants. It may be affected by the EEG. The growing recognition of the presence of a normal oscillator dynamics in the atalog of as generated strong interest in the direct modulation of endogenous oscillations. Future studies on various forms of neuromodulation and EEG alterations in unmedicated patients are needed. In all, the drop-out rates were higher in the sham group, which might be related to the lack of antidepressant effect. In future studies, we should make efforts to reduce the drop-out rate in the sham group. In summary, our trial provided preliminary evidence for the antidepressant effects of the larger long-term trials are needed to derive more reliable conclusions.

Our results suggest that the additional antidepressant effect of the as significant and lasted for at least 3 weeks and combining the intermittent antidepressants is a feasible and effective approach for the treatment of the antidepressant mechanism of the maintenance and the reduction of the overall mood in the left frontal lobe. Future research directions may include exploring more appropriate treatment parameters of tEE.

This study was funded by the National Natural Science Foundation of China (82271285) and the Jiangsu Provincial Key Laboratory of Neuropsychology (2021020204). The authors declare no competing interests.

Writing – review & editing: J. Zhou, X. Zhou, C. Wang, and C. Wang. Original draft: J. Zhou, X. Zhou, C. Wang, and C. Wang. Revision: J. Zhou, X. Zhou, C. Wang, and C. Wang. Final proofreading: J. Zhou, X. Zhou, C. Wang, and C. Wang. All authors contributed equally and significantly to writing this article. All authors have read and approved the final version. Correspondence: J. Zhou (jzhang@hust.edu.cn).

The authors declare no competing interests.

We would like to thank the doctors and nurses for their generous support during the conduct of the study and all the patients and their families for participating in this trial. We also thank the academic colleagues for providing the transcranial alternating current stimulation devices free of charge. It is our hope that the mentioned funders or companies in the introduction and performance of the study.

Supplemental data to this article can be found online at <https://doi.org/10.1016/j.brs.2024.07.001>.

This article represents the views of the authors and is not the responsibility of the journal. The copyright for this article is held by the author(s). All rights reserved. No part of this article may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior written permission of the publisher.

The authors have declared that they have no competing interests.

Received 15 October 2023; received in revised form 11 December 2023; accepted 10 January 2024.

© 2024 The Author(s). Published by Elsevier B.V.

Brain Stimulation 17 (2024) 760–768.

Brain Stimulation

in ang ong u en ing et al alidation of t e inese ersion
of t e amilton rating scale for de pression in adults it e ile s E ile s e a
i ou u u elia ilit and alidit of t e traditional inese
ersion of t e - in ai anese atients it e ile s ormos ed ssoc
iu iang ang u ng ari il ourne et al s c ometric
ro erties of t e inese ersions of t e uic in entor of de ressi e
m tomatolog clinician rating - - and self-re ort - - ffect
isord
iu elia ilit and alidit of t e itts urg slee ualit inde inese ournal
of s c iatr
er g odd allal am ell ernardo et al e alidit of t e
se erit and im ro ement scales as measures of clinical effecti eness suita le
for routine clinical use E al lin ract -
il ening ur ec ec antsreiter E ad erg alm ranscranial
alternating current stimulation for t e treatment of ma or de pression during
regnanc s c iatr es -
erlim an den E nde as ala is ig -fre uenc re etiti e transcranial
magnetic stimulation accelerates and en ances t e clinical res onse to
antide ressants in ma or de pression a meta-anal sis of randomi ed dou le- lind
and s am-controlled trials lin s c iatr e -
umi atta igonatti osa regni osa et al ranscranial